Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity

Waldman, 2020, A guide to cancer immunotherapy: from T cell basic science to clinical practice, Nat. Rev. Immunol., 20, 651, 10.1038/s41577-020-0306-5 Vesely, 2022, Resistance mechanisms to anti-PD cancer immunotherapy, Annu. Rev. Immunol., 40, 45, 10.1146/annurev-immunol-070621-030155 Jenkins, 2018, Mechanisms of resistance to immune checkpoint inhibitors, Br. J. Cancer, 118, 9, 10.1038/bjc.2017.434 Twumasi-Boateng, 2018, Oncolytic viruses as engineering platforms for combination immunotherapy, Nat. Rev. Cancer, 18, 419, 10.1038/s41568-018-0009-4 Su, 2023, A dual-responsive STAT3 inhibitor nanoprodrug combined with oncolytic virus elicits synergistic antitumor immune responses by igniting pyroptosis, Adv. Mater., 35, 10.1002/adma.202209379 Rehman, 2016, Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy, J. Immunother. Cancer, 4, 53, 10.1186/s40425-016-0158-5 Andtbacka, 2019, Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma, J. Immunother. Cancer, 7, 145, 10.1186/s40425-019-0623-z Kaufman, 2014, Primary overall survival (OS) from OPTiM, a randomized phase Ill trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma, J. Clin. Oncol., 32, 9008a, 10.1200/jco.2014.32.15_suppl.9008a Ferrucci, 2021, Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma, Cancers, 13, 10.3390/cancers13061383 Kanai, 2012, Effect of gamma34.5 deletions on oncolytic herpes simplex virus activity in brain tumors, J. Virol., 86, 4420, 10.1128/JVI.00017-12 Mossman, 2002, Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication, J. Virol., 76, 1995, 10.1128/JVI.76.4.1995-1998.2002 Orvedahl, 2007, HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein, Cell Host Microbe, 1, 23, 10.1016/j.chom.2006.12.001 Kurokawa, 2018, Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy, J. Natl. Cancer Inst., 110, 1123, 10.1093/jnci/djy033 Ngo, 2017, Mechanisms and functions of guanylate-binding proteins and related interferon-inducible GTPases: roles in intracellular lysis of pathogens, Cell. Microbiol., 19, e12791, 10.1111/cmi.12791 Tretina, 2019, Interferon-induced guanylate-binding proteins: guardians of host defense in health and disease, J. Exp. Med., 216, 482, 10.1084/jem.20182031 Li, 2017, Ubiquitination and degradation of GBPs by a Shigella effector to suppress host defence, Nature, 551, 378, 10.1038/nature24467 Zou, 2017, Guanylate-binding protein 1 inhibits nuclear delivery of Kaposi's sarcoma-associated herpesvirus virions by disrupting formation of actin filament, J. Virol., 91, 10.1128/JVI.00632-17 Zhang, 2018, Species-specific deamidation of cGAS by herpes simplex virus UL37 protein facilitates viral replication, Cell Host Microbe, 24, 234, 10.1016/j.chom.2018.07.004 Sun, 2020, DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity, Nat. Commun., 11, 6182, 10.1038/s41467-020-19941-0 Zhang, 2015, Herpesviral G protein-coupled receptors activate NFAT to induce tumor formation via inhibiting the SERCA calcium ATPase, PLoS Pathog., 11, 10.1371/journal.ppat.1004768 Zhang, 2016, IkappaB kinase epsilon is an NFATc1 kinase that inhibits T cell immune response, Cell Rep., 16, 405, 10.1016/j.celrep.2016.05.083 Song, 2020, KAT5 acetylates cGAS to promote innate immune response to DNA virus, Proc. Natl. Acad. Sci. USA, 117, 21568, 10.1073/pnas.1922330117 Zhong, 2020, Phosphorylation of cGAS by CDK1 impairs self-DNA sensing in mitosis, Cell Discov., 6, 26, 10.1038/s41421-020-0162-2 Mukherjee, 2015, Immunofluorescence-based methods to monitor DNA end resection, Methods Mol. Biol., 1292, 67, 10.1007/978-1-4939-2522-3_5 Praefcke, 2004, Identification of residues in the human guanylate-binding protein 1 critical for nucleotide binding and cooperative GTP hydrolysis, J. Mol. Biol., 344, 257, 10.1016/j.jmb.2004.09.026 Piro, 2017, Detection of cytosolic Shigella flexneri via a C-terminal triple-arginine motif of GBP1 inhibits actin-based motility, mBio, 8, 10.1128/mBio.01979-17 Ostler, 2014, Gamma interferon-induced guanylate binding protein 1 is a novel actin cytoskeleton remodeling factor, Mol. Cell. Biol., 34, 196, 10.1128/MCB.00664-13 Smith, 2021, Navigating the cytoplasm: delivery of the alphaherpesvirus genome to the nucleus, Curr. Issues Mol. Biol., 41, 171, 10.21775/cimb.041.171 Miranda-Saksena, 2018, Infection and transport of herpes simplex virus type 1 in neurons: role of the cytoskeleton, Viruses, 10, 10.3390/v10020092 Wandel, 2017, GBPs inhibit motility of Shigella flexneri but are targeted for degradation by the bacterial ubiquitin ligase IpaH9.8, Cell Host Microbe, 22, 507, 10.1016/j.chom.2017.09.007 Bommareddy, 2018, Oncolytic herpes simplex viruses as a paradigm for the treatment of cancer, Annu. Rev. Cancer Biol., 2, 155, 10.1146/annurev-cancerbio-030617-050254 Ge, 2020, Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety, J. Immunother. Cancer, 8 Nakao, 2020, Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade, Sci. Transl. Med., 12, 10.1126/scitranslmed.aax7992 Choi, 2011, Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12R beta(2) or IL-18R alpha (vol 18, pg 898, 2011), Gene Ther., 18, 942, 10.1038/gt.2011.72 Parker, 2000, Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors, Proc. Natl. Acad. Sci. USA, 97, 2208, 10.1073/pnas.040557897 Rosewell Shaw, 2017, Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer, Mol. Ther., 25, 2440, 10.1016/j.ymthe.2017.09.010 Kleinpeter, 2016, Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition, Oncoimmunology, 5, e1220467, 10.1080/2162402X.2016.1220467 Wang, 2020, An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses, Nat. Commun., 11 Wilcox, 2016, The herpes simplex virus neurovirulence factor gamma 34.5: revealing virus-host interactions, PLoS Pathog., 12, e1005449, 10.1371/journal.ppat.1005449 Manivanh, 2017, Role of herpes simplex virus 1 gamma34.5 in the regulation of IRF3 signaling, J. Virol., 91, 10.1128/JVI.01156-17 Yoo, 2014, Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects, Clin. Cancer Res., 20, 3787, 10.1158/1078-0432.CCR-14-0553 Nakashima, 2015, Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma, J. Clin. Invest., 125, 4269, 10.1172/JCI80713 Passer, 2010, Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication, Cancer Res., 70, 3890, 10.1158/0008-5472.CAN-10-0155 Crameri, 2018, MxB is an interferon-induced restriction factor of human herpesviruses, Nat. Commun., 9, 1980, 10.1038/s41467-018-04379-2 Tanaka, 2003, Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo, J. Virol., 77, 1382, 10.1128/JVI.77.2.1382-1391.2003 Richards, 2016, New tools to convert bacterial artificial chromosomes to a self-excising design and their application to a herpes simplex virus type 1 infectious clone, BMC Biotechnol., 16, 64, 10.1186/s12896-016-0295-4 Wang, 2013, Tracking viral genomes in host cells at single-molecule resolution, Cell Host Microbe, 14, 468, 10.1016/j.chom.2013.09.004